Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor
- 1 July 2012
- journal article
- Published by Elsevier BV in Molecular Immunology
- Vol. 51 (3-4), 263-272
- https://doi.org/10.1016/j.molimm.2012.03.023
Abstract
No abstract availableKeywords
Funding Information
- Pediatric Cancer Research Foundation and the Amy Phillips Charitable Foundation
This publication has 42 references indexed in Scilit:
- Functional Dichotomy between NKG2D and CD28-Mediated Co-Stimulation in Human CD8+ T CellsPLOS ONE, 2010
- Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor EradicationMolecular Therapy, 2010
- Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanomaCancer, 2010
- Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impairedBlood, 2009
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In VivoMolecular Therapy, 2009
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancerProceedings of the National Academy of Sciences of the United States of America, 2007
- Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockadeThe Journal of Experimental Medicine, 2006
- The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic FactorsNeoplasia, 2006
- PD‐1 inhibits T‐cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθFEBS Letters, 2004
- In situ expression of B7 and CD28 receptor families in human malignant melanoma: Relevance for T‐cell‐mediated anti‐tumor immunityInternational Journal of Cancer, 1995